Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC-1-50 for Relapsed/Refractory CD19+ B-ALL
NCT06641024Phase 1Not yet recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PTOC1 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Chongqing Precision Biotech. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 1 month. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
PTOC1
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06641024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641024.